Status:
COMPLETED
Study of Interest of Stiripentol and Carbamazepine in the Treatment of Patients With Pharmacoresistant Focal Epilepsies
Lead Sponsor:
Biocodex
Conditions:
Pharmacoresistant Focal Epilepsies
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
This is a monocentric, open-label clinical study, presenting a retrospective part and a prospective part, studying the data of patients with drug-resistant focal epilepsies and treated with the combin...
Eligibility Criteria
Inclusion
- Retrospective part of the research:
- The medical records of CRéER patients with the following criteria will be included in the retrospective part of the research by an investigator:
- With pharmacoresistant epilepsy, i.e. a history of failure of two well-conducted and well-tolerated antiepileptic treatment regimens, either as monotherapy or as combination therapy,
- Receiving or having received a treatment combining stiripentol and carbamazepine for a period of at least 15 days,
- Having at least one evaluation data after the initiation of treatment with stiripentol and carbamazepine (a follow-up visit after the initiation of the study treatment),
- For which an information note indicating the possibility of opposing the processing of data has been provided.
- Prospective part of the research:
- Among the patients whose medical records are included in the retrospective part of the research, those who meet the following criteria will be able to participate in the prospective part of the research:
- Currently treated with stiripentol in combination with carbamazepine for at least 15 days and still being followed in the center,
- Weighing at least 5 kg (minimum weight in accordance with the blood volume taken),
- Having read, or whose parents have read, the information note and signed the consent form. For children, if their level of understanding allows it, their consent will also be sought,
- Having sufficient knowledge, or whose parents or legal guardians have sufficient knowledge, of the French language to read, understand and complete the research documents,
- Members or beneficiaries of a social security scheme. These patients, both children and adults, will be welcomed at the CIC.
Exclusion
- \- Retrospective part of the research : Patients objecting to the collection of their data will not participate in the research.
- \- Prospective part of the research :
- Patients with the following criteria will not be able to participate in the prospective part of the research:
- Participating simultaneously in another interventional clinical trial or in a period of exclusion following a previous trial,
- Whose state of health does not allow him to give his consent,
- Under guardianship or curatorship,
- Under judicial protection or person deprived of liberty.
Key Trial Info
Start Date :
October 13 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 13 2024
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT05419180
Start Date
October 13 2022
End Date
June 13 2024
Last Update
July 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre de Référence Epilepsies Rares / Centre Investigation Clinique (CIC) - Hôpital Necker-Enfants Malades
Paris, France, 75015